Published in Cancer Res on August 15, 2004
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst (2009) 3.48
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A (2005) 3.22
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol (2010) 2.71
Platelets actively sequester angiogenesis regulators. Blood (2008) 2.47
Human body fluid proteome analysis. Proteomics (2006) 2.39
A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights (2007) 2.39
Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med (2012) 2.06
The blood peptidome: a higher dimension of information content for cancer biomarker discovery. Nat Rev Cancer (2006) 1.79
A Proteomic Approach for the Diagnosis of 'Oketsu' (blood stasis), a Pathophysiologic Concept of Japanese Traditional (Kampo) Medicine. Evid Based Complement Alternat Med (2007) 1.77
Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer (2007) 1.77
Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterology (2006) 1.72
Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn (2006) 1.70
Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry. World J Gastroenterol (2006) 1.60
Serum peptidome for cancer detection: spinning biologic trash into diagnostic gold. J Clin Invest (2006) 1.52
Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer (2010) 1.51
Identifying molecular markers for the early detection of pancreatic neoplasia. Semin Oncol (2007) 1.49
Proteomic contributions to personalized cancer care. Mol Cell Proteomics (2008) 1.46
Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics (2008) 1.32
No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. Br J Cancer (2007) 1.30
The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. Cancer Epidemiol Biomarkers Prev (2010) 1.25
Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel. Br J Cancer (2008) 1.21
Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol (2007) 1.20
Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci U S A (2007) 1.20
Early detection of ovarian cancer. Biomark Med (2008) 1.20
Identification of candidate biomarkers in ovarian cancer serum by depletion of highly abundant proteins and differential in-gel electrophoresis. Electrophoresis (2010) 1.19
Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis. Br J Cancer (2006) 1.18
An empirical assessment of validation practices for molecular classifiers. Brief Bioinform (2011) 1.13
Identifying biomarkers from mass spectrometry data with ordinal outcome. Cancer Inform (2007) 1.09
AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration. Exp Mol Med (2011) 1.08
Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch (2006) 1.05
Protein biomarkers of ovarian cancer: the forest and the trees. Future Oncol (2012) 1.05
Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics (2008) 1.04
Early Detection of Cancer: Immunoassays for Plasma Tumor Markers. Expert Opin Med Diagn (2009) 1.04
In 2014, can we do better than CA125 in the early detection of ovarian cancer? World J Biol Chem (2014) 1.04
Dielectrophoretic differentiation of mouse ovarian surface epithelial cells, macrophages, and fibroblasts using contactless dielectrophoresis. Biomicrofluidics (2012) 1.02
Validation of candidate serum ovarian cancer biomarkers for early detection. Biomark Insights (2007) 1.00
Deep depletion of abundant serum proteins reveals low-abundant proteins as potential biomarkers for human ovarian cancer. Proteomics Clin Appl (2009) 1.00
Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis (2008) 0.99
Ovarian cancer biomarkers: current options and future promise. J Natl Compr Canc Netw (2008) 0.98
Novel serum protein biomarker panel revealed by mass spectrometry and its prognostic value in breast cancer. Breast Cancer Res (2014) 0.98
Applications of SELDI-MS technology in oncology. J Cell Mol Med (2008) 0.98
Clinical proteomics: present and future prospects. Clin Biochem Rev (2006) 0.97
Insights into the field carcinogenesis of ovarian cancer based on the nanocytology of endocervical and endometrial epithelial cells. Int J Cancer (2013) 0.97
New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol (2006) 0.97
Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer. J Proteomics (2013) 0.97
Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Mol Diagn Ther (2013) 0.96
Proteomic analyses of human plasma: Venus versus Mars. Transfusion (2011) 0.95
A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. J Proteome Res (2011) 0.95
Nanostructured optical photonic crystal biosensor for HIV viral load measurement. Sci Rep (2014) 0.95
Decreased levels of serum glutathione peroxidase 3 are associated with papillary serous ovarian cancer and disease progression. J Ovarian Res (2011) 0.95
Strategy for degradomic-peptidomic analysis of human blood plasma. J Proteome Res (2010) 0.95
Microheterogeneity of transthyretin in serum and ascitic fluid of ovarian cancer patients. BMC Cancer (2005) 0.94
The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile. BMC Med Genomics (2008) 0.94
The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med (2006) 0.93
An integrated approach utilizing proteomics and bioinformatics to detect ovarian cancer. J Zhejiang Univ Sci B (2005) 0.93
Mass spectrometry-based proteomic profiling of lung cancer. Proc Am Thorac Soc (2009) 0.93
A simulation-approximation approach to sample size planning for high-dimensional classification studies. Biostatistics (2009) 0.92
An insight into the changes in human plasma proteome on adaptation to hypobaric hypoxia. PLoS One (2013) 0.92
Breast cancer proteomics: a review for clinicians. J Cancer Res Clin Oncol (2011) 0.91
Development of multiplexed bead-based immunoassays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PLoS One (2012) 0.91
Proteomic analysis of serum yields six candidate proteins that are differentially regulated in a subset of women with endometriosis. Fertil Steril (2009) 0.91
Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. PLoS One (2011) 0.91
Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma. Anal Bioanal Chem (2010) 0.91
Proteomic analysis of HCV cirrhosis and HCV-induced HCC: identifying biomarkers for monitoring HCV-cirrhotic patients awaiting liver transplantation. Transplantation (2009) 0.90
Transthyretin, a biomarker for nutritional status and ovarian cancer. Cancer Res (2005) 0.90
Proteomic technology for biomarker profiling in cancer: an update. J Zhejiang Univ Sci B (2006) 0.90
Differentially Expressed Proteins in Chronic Active Hepatitis, Cirrhosis, and HCC Related to HCV Infection in Comparison With HBV Infection: A proteomics study. Hepat Mon (2013) 0.89
An In Vitro Diagnostic Multivariate Index Assay (IVDMIA) for Ovarian Cancer: Harvesting the Power of Multiple Biomarkers. Rev Obstet Gynecol (2012) 0.89
A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium. BMC Cancer (2013) 0.89
Identification of serum CCL15 in hepatocellular carcinoma. Br J Cancer (2013) 0.88
Prevalence of antitumor antibodies in laying hen model of human ovarian cancer. Int J Gynecol Cancer (2009) 0.88
A new approach for the analysis of mass spectrometry data for biomarker discovery. AMIA Annu Symp Proc (2006) 0.88
Reproducibility of SELDI Spectra Across Time and Laboratories. Cancer Inform (2011) 0.87
Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification. J Cancer Res Clin Oncol (2007) 0.87
Ovarian cancer: in search of better marker systems based on DNA repair defects. Int J Mol Sci (2013) 0.87
Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Proteomics Clin Appl (2008) 0.87
Serum biomarker profile associated with high bone turnover and BMD in postmenopausal women. J Bone Miner Res (2008) 0.86
Challenges in Biomarker Discovery: Combining Expert Insights with Statistical Analysis of Complex Omics Data. Expert Opin Med Diagn (2013) 0.86
MALDI-MS-Based Profiling of Serum Proteome: Detection of Changes Related to Progression of Cancer and Response to Anticancer Treatment. Int J Proteomics (2012) 0.85
Plasma proteome changes associated with refractory cytopenia with multilineage dysplasia. Proteome Sci (2011) 0.85
Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol (2011) 0.85
Enzymes and related proteins as cancer biomarkers: a proteomic approach. Clin Chim Acta (2007) 0.85
Identification of haptoglobin and apolipoprotein A-I as biomarkers for high altitude pulmonary edema. Funct Integr Genomics (2011) 0.85
Site-specific glycan microheterogeneity of inter-alpha-trypsin inhibitor heavy chain H4. J Proteome Res (2014) 0.85
Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res (2009) 0.85
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? Int J Mol Sci (2013) 0.84
Moving forward in colorectal cancer research, what proteomics has to tell. World J Gastroenterol (2007) 0.84
[Novel prognostic marker in invasive breast cancer. ITIH5 expression is abrogated by aberrant promoter methylation]. Pathologe (2008) 0.84
Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. Br J Cancer (2010) 0.84
In-silico prediction of blood-secretory human proteins using a ranking algorithm. BMC Bioinformatics (2010) 0.84
Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics. J Biomed Opt (2012) 0.84
Proteomics and mass spectrometry for cancer biomarker discovery. Biomark Insights (2007) 0.84
Alterations in cerebrospinal fluid proteins in a presymptomatic primary glioma model. PLoS One (2012) 0.84
Proteomics of ovarian cancer: functional insights and clinical applications. Cancer Metastasis Rev (2015) 0.84
Comprehensive quantitative analysis of ovarian and breast cancer tumor peptidomes. J Proteome Res (2014) 0.83
Discovering differential protein expression caused by CagA-induced ERK pathway activation in AGS cells using the SELDI-ProteinChip platform. World J Gastroenterol (2008) 0.83
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
Evidence based selection of housekeeping genes. PLoS One (2007) 7.90
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med (2011) 7.82
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem (2002) 4.42
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol (2007) 4.06
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol (2008) 3.54
Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain (2011) 3.48
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One (2009) 3.33
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol (2005) 3.31
Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol (2005) 3.15
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
A genetically defined model for human ovarian cancer. Cancer Res (2004) 3.02
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation (2007) 2.72
Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol (2010) 2.71
HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics (2005) 2.71
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest (2008) 2.63
Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol (2003) 2.58
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study. Gynecol Oncol (2006) 2.47
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. J Natl Cancer Inst (2014) 2.40
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. J Proteome Res (2009) 2.33
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Mechanical stiffness grades metastatic potential in patient tumor cells and in cancer cell lines. Cancer Res (2011) 2.32
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol (2007) 2.20
Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant. Am J Hum Genet (2002) 2.17
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park) (2013) 2.17
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem (2005) 2.13
G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest (2012) 2.12
The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. Clin Cancer Res (2011) 2.09
Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res (2002) 2.07
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol (2010) 2.05
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations. Clin Chem (2009) 2.01
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol (2010) 1.94
Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res (2006) 1.93
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91
Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol (2012) 1.90
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (2002) 1.90
Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med (2009) 1.88
The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncol (2013) 1.83
Proteomics: a new diagnostic frontier. Clin Chem (2006) 1.82
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu. Cancer Prev Res (Phila) (2009) 1.78
Early detection of ovarian cancer. Dis Markers (2007) 1.77
Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol (2006) 1.75